IMMUNITYBIO, INC. Deferred Tax Liabilities, Net
IMMUNITYBIO, INC. (IBRX) had Deferred Tax Liabilities, Net of $0 as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-02-23
- 2025-12-31: Deferred Tax Liabilities, Net $0.00.
- 2024-12-31: Deferred Tax Liabilities, Net $139.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $148.00K.
- 2022-12-31: Deferred Tax Liabilities, Net $158.00K.
| Period end | Deferred Tax Liabilities, Net | Deferred Tax Liabilities, Net as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 | |
| 2024-12-31 | $139.00K 10-K · filed 2026-02-23 | |
| 2023-12-31 | $148.00K 10-K · filed 2025-03-03 | |
| 2022-12-31 | $158.00K 10-K · filed 2024-03-19 | |
| 2021-12-31 | $162.00K 10-K · filed 2023-03-01 | |
| 2020-12-31 | $170.00K 10-K · filed 2022-03-01 | $0.00 10-K · filed 2021-03-04 |
| 2019-12-31 | $3.11M 8-K/A · filed 2021-04-22 | $0.00 10-K · filed 2020-03-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-25 | |
| 2017-12-31 | $498.00K 10-K · filed 2019-03-13 | |
| 2016-12-31 | $996.00K 10-K · filed 2018-03-12 | |
| 2015-12-31 | $1.17M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |